alpha-aminopyridine has been researched along with Hepatic Insufficiency in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Houk, B; Pithavala, YK; Ruiz-Garcia, A | 1 |
| Chen, J; Golla, G; Hirano, M; Lin, T; Majumdar, T; Meyers, D; Pal, P; Pinot, P; Rebello, S; Sunkara, G | 1 |
2 trial(s) available for alpha-aminopyridine and Hepatic Insufficiency
| Article | Year |
|---|---|
Population pharmacokinetic model with time-varying clearance for lorlatinib using pooled data from patients with non-small cell lung cancer and healthy participants.
Topics: Adult; Aminopyridines; Anaplastic Lymphoma Kinase; Carcinoma, Non-Small-Cell Lung; Female; Healthy Volunteers; Hepatic Insufficiency; Humans; Lactams; Lung Neoplasms; Male; Middle Aged; Prognosis; Protein-Tyrosine Kinases; Proto-Oncogene Proteins; Proton Pump Inhibitors; Pyrazoles; Renal Insufficiency; Serum Albumin | 2021 |
Effect of Hepatic Impairment on the Pharmacokinetics of Pradigastat, a Diacylglycerol Acyltransferase 1 (DGAT1) Inhibitor.
Topics: Acetates; Aminopyridines; Body Mass Index; Diacylglycerol O-Acyltransferase; Enzyme Inhibitors; Female; Glucuronides; Hepatic Insufficiency; Humans; Hyperlipoproteinemia Type I; Male; Middle Aged; Protein Binding | 2015 |